Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Files Form 10 w/ SEC.....
...read on
http://www.sec.gov/Archives/edgar/data/1015441/000114420411005836/v206526_10-12g.htm
;)
Yes, this definitely has never been an I-hub stock ... and that's probably a good thing.
Wow --- Dead board. ZZZZZZZZZZZZZzzzzzzzzzzzzz
I called a while back and the trial coodinator said that the trial is still open to enrollment, which means that it is a long way from being completed. I get the feeling that this particular cancer vaccine is not looking promising to the women suffering from ovarian cancer.
Otherwise I think they would have reached their limit by now. Then again, it's possible they're enrolling all comers.
Is AVXT your next ten bagger stock?
AVAX Technologies, Inc. pipeline is highly undervalued with market cap of $10 M.
See e.g. http://www.americanchronicle.com/articles/view/123915
It is old but ...
Website www.avax-tech.com is being updated. Please check back soon.
Looks more like the Estimated end to the primary completion date has been pushed ahead to December of *2011*.
Are we waiting another 11 1/2 months for news??????
Somebody have any idea what is going on???
Here it is, trial is done (primary)
Estimated Enrollment: 42
Study Start Date: April 2008
Estimated Study Completion Date: March 2012
Estimated Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Old :
Estimated Enrollment: 42
Study Start Date: April 2008
Estimated Study Completion Date: March 2011Estimated Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Something was updated on January 7th, trying to pick out what it was.
http://clinicaltrials.gov/ct2/show/NCT00660101?term=avax&rank=3
yes & many more to come :)
Looks like the start of a good day.
Thanks Much, have a good one! ;O)
Someone else would be better but I think March is the expected release of results. However I think it ends this month. Could go lower and was at .04 a bit ago. I was waiting for .03's but big volume the other day got my attention so I'm in for a taste and adding if we go down. Superfly has a post with the trials a few down so I'd check there for info. GLTU
when are the results do out? I haven't been following this for awhile and you guys seem to be up on it. Thanks!
Picked up 2K @ .07 because volume looking good.
when are the results do out? I haven't been following this for awhile and you guys seem to be up on it. Thanks!
insiders know first i think this volume are from there imo
http://clinicaltrials.gov/ct2/show/NCT00660101?term=avax&rank=3
Still nothing updated, not sure what's going on.
time is running out to get cheapies imo :)
I agree and that's why I at least got a taste yesterday. To 'flip' I'll need to add more and hopefully I will soon.
Nope looks like we may go up from now on.
but this time could be spectacular if the results are good ;)
This happened with the last run up. Someone grabbed a bunch of shares and waited until PPS dipped, then did it again but kept buying and then day traders jumped in and we went WWWWEEEEE
.06x.065 ut without volume hmmmm :)
Picked up a taste of 10K @ .056 Just in case...Hoping to add more at lower PPS in the coming weeks but MUST have some so I bit.
Had to do first aid/CPR/AED training today so I just got in and WOW!!! GREAT VOLUME!
Hope to get a taste in a few days cause it's going to RUN! Almost 1.4 mil traded and only up 26%
This happened on the last run a couple weeks before the run. I'd expect a mini-run before results are made public and if it's positive, a HUGE MOVE to the upside.
83k block at .06 nice
Zilla stop buying all the shares !!
Thats a nice chuck of volume for AVXT...Nice :- )
ARCA is making it go up with big buys. I won't be getting in now.
GLTU and the other AVXT shareholders.
someone just grabbed a bunch hmmmm good OVax® news near? :)
Haha, yeah man I watched ADLS down there and just didnt have the will to buy it. ACTC is a scam though, will never buy that thing especially after seeing who financed them.
All i've got right now is some AVXT @ .045, a bunch of ISAC @~.09 and lots of cash, you might like that ISAC since you like almost dead companies lol.
There's so many trades out there including this one, it feels kind of like last April though and I think we might pay for this fun later in the year if the dollar strengthens like I bet it does.
I want some under .03 but they don't want to sell them to me there. WAAHHAHHHHH. (LOL)
Good to see you Superfly.
I'm not happy with selling my ADLS @ .0155 last week, my NVLT .0225 the week before or my ACTC under .10 a month ago. (LOL)
Tronox holding up well and we both got out too early there. Newtech turned me on to them and we we're both here. He had 700K under .02 and sold in the .20's!!! I'd like to repeat that.
Watching ABKFQ but it's not doing what I was expecting. DOPE!!!
PS STAY AWAY from ILNS unless it's a day/momo trade. I sold on a POP @ .0043 but was in at .005? went below .002 and looks like it will again soon. DILLUTION BIG TIME 8K 2 weeks ago.
AVXT I'll be watching for volume before news and then I might buy even if it doesn't get below .03
Watch this for an update to the trial page (Last Updated March 8 2010)
http://clinicaltrials.gov/ct2/show/NCT00660101?term=avax&rank=3
Hi Lefty, I just wanted to find this post for later.
That was moving. Thanks for sharing that.
I'm confident from the results that I've read about that immunotherapy for cancer, i.e. priming one's own immune system to destroy cancer, will play a significant role in the future of cancer medicines.
What I'm still not totally convinced of is whether AVXT's method will be part of the picture. I found something out this weekend that did give me a confidence boost about AVXT. Dr. Berd, who developed the OVAX and MVAX, now carries the title of national director of immunology at the Cancer Treament Centers of America.
This is of course where the ovarian cancer trial is taking place, so hopefully he'll guide his therapy to approval with the FDA.
i got $ ready waiting for any dip i got some but i need more before january 2011 :)
Cha-Ching.
Dr. Coukos anticipates that in the future, immunotherapy in combination with surgery and chemotherapy will become a standard of care for ovarian cancer.
As it points out in the article, a big reason why the cancer vaccine has a higher than usual chance of approval by the FDA is:
no toxicity.
You can add the cancer vaccine to any cancer treatment regimen and you don't have to worry about the chemo killing the patient or making him/her too ill to stand it.
and results are just around the corner the time is now to start loading the anticipation alone of how big this could be is insane.
http://clinicaltrials.gov/show/NCT00660101
Estimated Study Completion Date: March 2011
Estimated Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
No I hadn't seen that, nice find.
check the CTCA Outcomes Data on survival on different cancer's this guys has !above average vs national
wow impresive! you got the next DNDN here imo im in !
http://www.cancercenter.com/press-center/quality-story.cfm
CTCA currently tracks its clinical outcomes for some cancer types and compares them with those in an available national database. In our outcomes sections, you will find data for patients with a specific cancer type who treated at CTCA hospitals compared with patient data from the National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) database.
zilla you see this? http://www.cancercenter.com/ovarian-cancer/vaccine.cfm
The ovarian cancer vaccine is an innovative ovarian cancer treatment we are pioneering
Thanks, "lefty", let's hope there will be no more suspensions and that the results will be great.
Estimated primary completion date: Jan '11
Estimated study completion date: March '11
estimated enrollment is 42 patients. So the results will be made public sometime between January 2011 and March 2011.
Ya can't do salvage chemotherapy regimens on dead people. The reason that the number of salvage doses was increased from 2 to four last winter is because the people taking AVXT's therapy for ovarian cancer are surviving longer than expected.
I should restate that part about something concrete to go on. There is something concrete here to definitely justify buying more at this price. I was specifically meaning that the company is not releasing any info.
The buying action over the last few months coupled with the past history of the stock definitely signal a buy. Very little selling in this range combined with past spikes in buying that led to the stock reaching the .20s and .40s in recent years is what makes this an attractive buy at this price.
Add that with the reported success of the previous melanoma trial, the complete response of one of the patients of the previous Phase I ovarian cancer trial, the FDA's approval of dendreon's provenge using a very similar treatment, and NWBO's seeming success with it's brain cancer treatment.
It all adds up to a buy.
Down 20% on 339,000 shares.
Nite was bid .057/ask .061 I'll be watching them closely. I never saw who made us go up the past couple days but I'll try to see who wants to control the PPS.
I'm still up 165% so keep bringing it down or POP it for some profit taking.
Nice low volume to make people forget.
Still holding and will add in a few weeks if we slowly slip back down on low volume. It's a game just remember to buy low and sell high. If March 2011 is the last known target date for info, then we should be able to get back to .03 especially if there's an overall market sell-off. GLTU
.07 still up 200% come on you can do better.
Followers
|
34
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1605
|
Created
|
05/25/05
|
Type
|
Free
|
Moderators |
Industry Center - Biotechnology
Contact Information | |
Address: | 2000 Hamilton St., Ste. 204 Philadelphia, PA 19130 |
Phone: | 215-241-9760 |
Fax: | 215-241-9684 |
Key People | |
• | CEO: Adele Sommerfeld |
• | BOD: Andrew W. Dahl Sc.D.; Serge Morrell |
| |||
|
Business Summary |
---|
AVAX Technologies, Inc., a development stage biotechnology company, together with its subsidiaries, engages in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer in the United States and Europe. The company's autologous cell vaccine candidates include M-Vax under Phase III clinical status, which is used for the treatment of melanoma; L-Vax under Phase I-II clinical status that is used for the treatment of non-small cell lung cancer; and O-Vax under Phase I-II clinical status, which is used for the treatment of ovarian cancer. It also offers biological manufacturing services to other biotechnology and pharmaceutical companies; and contract manufacturing services in for cell and gene therapy, and biological products in France. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.
PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies, Inc. (Pink Sheets:AVXT.pk - News) ("AVAX" or the "Company") today announced that it filed a Form 10 with the Securities and Exchange Commission ("SEC"). Upon the effectiveness of this Form 10, AVAX will once again become a publicly reporting company. The Company intends to seek to have its common stock trade on the Over-the-Counter Bulletin Board.
The Company's Form 10, which contains among other things, recent information about the Company's business, operations, financial results and capitalization, can be accessed through the website maintained by the SEC at www.sec.gov.
About AVAX Technologies, Inc.
AVAX Technologies, Inc. is a biotechnology company headquartered in Philadelphia, PA. The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics.
The Company's AC Vaccine platform is a therapeutic cancer vaccine.
Forward-Looking Statements
Certain statements in this release are "forward-looking" statements. Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of M-VAX® and its other vaccine candidates, as well as other important factors discussed in the Company's Form 10. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements or to reflect the occurrence of unanticipated events.
Press Releases & AVAX Information:
https://en.wikipedia.org/wiki/Avax_Technologies
http://www.reuters.com/article/2014/01/08/ctca-trial-cancer-idUSnPnDChVKwJ+16d+PRN20140108
http://ih.advfn.com/p.php?pid=nmona&article=61013370
http://www.bizjournals.com/philadelphia/blog/health-care/2014/02/ovarian-cancer-vaccine-testing-expands.html
http://www.avax-tech.com/about/pdfs/avaxfactsheet.pdf
Published: Aug 4, 2015 7:31 p.m. ET
PHILADELPHIA, Aug 04, 2015 (BUSINESS WIRE) -- AVAX Technologies, Inc., (“AVAX” or “The Company”) (AVXT – OTCMKTS), a leading developer of proprietary cancer immunotherapy products, has signed a Settlement & Release Agreement with Cancer Treatment Centers of America Inc. (“CTCA”) to positively resolve the existing debt obligations owed to CTCA.
Under the terms of the Settlement Agreement, CTCA has agreed to settle its $5,826,464.73 Judgment against AVAX in exchange for 860,000 Series A Convertible Preferred Shares at a consideration of $5.00 per share, and a one-time payment of $1.5 million in cash. Firebird Management, a shareholder and a creditor of AVAX, has agreed to swap its outstanding debt for the Series A Convertible Preferred Shares also at a consideration of $5.00 per share.
Andrew Dahl, AVAX Board Member noted, “we are extremely happy to be able to move forward with the reorganization of AVAX’s balance sheet and look forward to re-commencing the important planned clinical trials at AVAX. Our previous work with CTCA on clinical programs has been very successful.”
Richard Rainey, Acting Chief Executive Officer of AVAX, stated, “We are pleased that throughout the development of our AC Vaccine® platform, all of our data has remained consistently positive and has supported further development of the treatment. We feel our immunotherapy platform is consistent with recently approved products and could be additive to the benefits achieved in helping patients with cancer.”
SGC Canada Inc., is acting on behalf of AVAX with its creditors in negotiating its informal restructuring plan. David Holden, the Senior Corporate Advisor of SGC states that “AVAX will be effectively debt-free once the Financial Restructuring & Refinancing Plan is completed.” The Board of AVAX has previously approved the engagement of Phoenix Corporate Finance Inc., a corporate finance firm which specializes in alternative financing, to advise, structure, and facilitate the distribution of a proposed Private Placement financing. through select securities dealers in the US and Canada. AVAX intends to raise $45 million to fund its next round of clinical testing through the issuance of the Series A Convertible Preferred Shares.
AVAX TECHNOLOGIES WEBSITE IS NOW ACTIVE: WWW.AVAX-TECH.COM/
AVAX TECHNOLOGIES, INC APPOINTS NEW CEO: ADELE SOMMERFELD 10/19/2015
http://www.prnewswire.com/news-releases/avax-technologies-inc-announces-the-appointment-of-chief-executive-officer-300161646.html
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |